| Issue |
Section |
Title |
File |
| Vol 21, No 4 (2019) |
CLINICAL ONCOLOGY |
The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution |
(Rus)
|
| Vol 22, No 1 (2020) |
CLINICAL ONCOLOGY |
Solitary (extramedullary) plasmocytoma. Clinical recommendations |
(Rus)
|
| Vol 22, No 1 (2020) |
CLINICAL ONCOLOGY |
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
(Rus)
|
| Vol 22, No 1 (2020) |
CLINICAL ONCOLOGY |
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer |
(Rus)
|
| Vol 22, No 2 (2020) |
Conference Proceedings |
Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic |
(Rus)
|
| Vol 22, No 2 (2020) |
Original Article |
Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52 |
(Rus)
|
| Vol 22, No 2 (2020) |
Conference Proceedings |
New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas |
(Rus)
|
| Vol 22, No 2 (2020) |
Review |
Accompanying therapy in oncohematological patients with secondary immunodeficiency |
(Rus)
|
| Vol 22, No 2 (2020) |
Best Practice |
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience |
(Rus)
(Eng)
|
| Vol 22, No 2 (2020) |
Original Article |
First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
Multiple myeloma |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy |
(Rus)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas |
(Rus)
|
| Vol 23, No 2 (2021) |
CLINICAL ONCOLOGY |
Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization |
(Rus)
|
| Vol 23, No 3 (2021) |
CLINICAL ONCOLOGY |
Extrapulmonary small cell carcinoma. Literature review |
(Rus)
|
| Vol 23, No 4 (2021) |
CLINICAL ONCOLOGY |
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III |
(Rus)
|
| Vol 24, No 1 (2022) |
CLINICAL ONCOLOGY |
Immuno-morphological characteristics of bone marrow in patients with ovarian cancer |
(Rus)
|
| Vol 24, No 1 (2022) |
CLINICAL ONCOLOGY |
Therapy of lymphoproliferative diseases in the era of COVID-19: challenges and solutions |
(Rus)
|
| Vol 24, No 1 (2022) |
CLINICAL ONCOLOGY |
From the editor-in-chief of the journal "Modern Oncology" Academician of the Russian Academy of Sciences I.V. Poddubnaya |
(Rus)
|
| Vol 24, No 1 (2022) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| Vol 24, No 3 (2022) |
CLINICAL ONCOLOGY |
Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study |
(Rus)
|
| Vol 24, No 2 (2022) |
CLINICAL ONCOLOGY |
Risk of discrimination against Russian citizens in providing medical care abroad as a health care trend |
(Rus)
|
| Vol 24, No 3 (2022) |
CLINICAL ONCOLOGY |
The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study |
(Rus)
|
| Vol 24, No 3 (2022) |
CLINICAL ONCOLOGY |
Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: Prospective cohort study |
(Rus)
|
| Vol 25, No 1 (2023) |
CLINICAL ONCOLOGY |
Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study |
(Rus)
|
| Vol 25, No 2 (2023) |
CLINICAL ONCOLOGY |
Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study |
(Rus)
|
| Vol 25, No 2 (2023) |
CLINICAL ONCOLOGY |
Heterogeneous diffuse large B-cell lymphoma: accurate diagnosis as a key to successful therapy. A review |
(Rus)
|
| Vol 25, No 2 (2023) |
CLINICAL ONCOLOGY |
Challenges and perspectives of first-line therapy in patients with diffuse B-cell lymphoma: A review |
(Rus)
|
| Vol 25, No 3 (2023) |
CLINICAL ONCOLOGY |
Diffuse large B-cell lymphoma: strokes to the epidemiological portrait. A review |
(Rus)
|
| Vol 25, No 3 (2023) |
CLINICAL ONCOLOGY |
An interdisciplinary approach to the management of oncohematological patients with immunodeficiency: clinical cases. A review |
(Rus)
|
| Vol 25, No 3 (2023) |
ИСТОРИЯ МЕДИЦИНЫ |
Memorial lecture to the 100th anniversary of the birth of Professor Yu.I. Lorie |
(Rus)
|
| Vol 25, No 4 (2023) |
CLINICAL ONCOLOGY |
Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas? |
(Rus)
|
| Vol 25, No 4 (2023) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| Vol 26, No 2 (2024) |
Articles |
Immunohistochemical factors of prognosis of immunotherapy for metastatic melanoma: А prospective and retrospective study |
(Rus)
|
| Vol 26, No 2 (2024) |
Articles |
Diffuse large B-cell lymphoma and follicular lymphoma: problem state in Russia |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Role of immunohistochemical prognostic factors in various types of immunotherapy for metastatic melanoma: A retro-prospective study |
(Rus)
|
| Vol 27, No 1 (2025) |
Articles |
Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Clinical significance of PET/CT in the diagnosis of primary adrenal malignancies |
(Rus)
|
| Vol 26, No 4 (2024) |
Articles |
Peritoneal lymphomatosis as the only manifestation of diffuse B-cell large cell lymphoma: A clinical case |
(Rus)
|
